NEW YORK (Reuters Health) – In patients with type 2 diabetes, glycemic control is better and weight loss is sustained up to 84 weeks with exenatide once weekly…
NEW YORK (Reuters Health) – Increases in fasting blood sugar levels are often seen in patients starting niacin, sometimes to a level that suggests new onset of type…
NEW YORK (Reuters Health) – Results of a study confirm that treatment with dapagliflozin helps patients with type 2 diabetes lose weight in addition to improving their blood…
NEW YORK (Reuters Health) – The glucagon-like peptide 1 analog taspoglutide administered subcutaneously once weekly improves glycemic control and reduces body weight in drug-naive patients with type 2…
NEW YORK (Reuters Health) – If lifestyle changes are not enough to control type 2 diabetes, metformin should be the first oral agent added to treatment, according to…
NEW YORK (Reuters Health) – Patients with type 2 diabetes who don’t have retinopathy at baseline have a relatively low risk of developing eye complications during 5 to…
NEW YORK (Reuters Health) – Fenofibrate is safe to use in patients with type 2 diabetes and moderate renal impairment, researchers conclude in a report online December 30…
NEW YORK (Reuters Health) – Based on the 2010 American Diabetes Association’s definition of prediabetes, the condition is present in over a third of psychiatric inpatients treated with…
NEW YORK (Reuters Health) – Parental fear of hypoglycemia probably blunts the potential benefits of continuous glucose monitoring in children with type 1 diabetes, researchers conclude in a…
NEW YORK (Reuters Health) – Cirrhosis and hepatitis are associated with the occurrence of hepatocellular carcinoma (HCC) in patients with diabetes, and hepatitis C is of particular importance,…